Table 1.
Description of the HGDS cohort (n = 333)
| Characteristics | HIV−, n = 126 |
HIV+, n = 207 |
All participants, n = 333 | ||
|---|---|---|---|---|---|
| Without inhibitor, n = 106 | With inhibitor, n = 20 | Without inhibitor, n = 167 | With inhibitor, n = 40 | ||
| Median age, y | 10.2 | 10.4 | 13.2 | 13.4 | 12.3 |
| Type of bleeding disorder, no. (%) | |||||
| Hemophilia A | 73 (68.9) | 18 (90.0) | 145 (86.8) | 38 (95.0) | 274 (82.3) |
| Hemophilia B | 26 (24.5) | 2 (10.0) | 21 (12.6) | 1 (2.5) | 50 (15.0) |
| von Willebrand disease | 5 (4.7) | 0 (—) | 1 (0.6) | 1 (2.5) | 7 (2.1) |
| Other | 2 (1.9) | 0 (—) | 0 (—) | 0 (—) | 2 (0.6) |
| Clotting factor level (n=327), no. (%) | |||||
| Less than 0.01 IU/mL | 58 (56.3) | 16 (80.0) | 130 (78.8) | 38 (97.4) | 242 (74.0) |
| 0.01-0.05 IU/mL | 36 (35.0) | 3 (15.0) | 23 (13.9) | 1 (2.6) | 63 (19.3) |
| More than 0.05 IU/mL | 9 (8.7) | 1 (5.0) | 12 (7.3) | 0 (0.0) | 22 (6.7) |
| Ethnic composition, no. (%) | |||||
| European American | 77 (72.6) | 15 (75.0) | 117 (70.1) | 32 (80.0) | 241 (72.4) |
| Hispanic | 15 (14.2) | 4 (20.0) | 27 (16.2) | 4 (10.0) | 50 (15.0) |
| African American | 13 (12.3) | 1 (5.0) | 19 (11.4) | 3 (7.5) | 36 (10.8) |
| Other | 1 (0.9) | 0 (0.0) | 4 (2.4) | 1 (2.5) | 6 (1.8) |
(—) indicates 0.0%.